

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Michel Xilinas et al.	<b>Examiner:</b>	Kendra D. Carter
<b>Serial No.:</b>	10/717,182	<b>Art Unit:</b>	1617
<b>Filed:</b>	November 18, 2003	<b>Docket:</b>	18381A
<b>For:</b>	USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE	<b>Dated:</b>	August 4, 2009

**Confirmation No.:** 5994

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**STATUS**


Sir:

Applicants inquire of the status of the Information Disclosure Statement filed on December 23, 2004. Applicants have not received any acknowledgement that the references cited therein, except B02 and B06, were considered by the USPTO.

Applicants have reviewed Private PAIR and note that the aforementioned IDS is in the file wrapper.

Applicants respectfully request that the USPTO make all of the references listed therein of record in the above-identified application if it has not yet done so. If the USPTO requires a copy of the IDS referred to herein, Applicants will gladly file another copy thereof.

Respectfully Submitted,

  
Mark J. Cohen  
Registration No. 32,211


SCULLY, SCOTT, MURPHY & PRESSER, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
516-742-4343 - Telephone  
516-742-4366 - Fax  
MJC/ech

---

**CERTIFICATION OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website, on August 4, 2009.

Dated: August 4, 2009

  
Mark J. Cohen